Viloxazine Extended-Release: A Clinical Review for Adult ADHD Treatment

Viloxazine ER (Qelbree), a norepinephrine reuptake inhibitor, is FDA-approved for ADHD in adults and showed significant symptom reduction and improved executive function in a 6-week randomized controlled trial. The medication demonstrated sustained benefits over 24 months with good tolerability, with insomnia and headache as the most common side effects and no significant cardiovascular or hepatic safety concerns.